[1]陈端英,何孙本,黄旭日,等.MicroRNA-16-5p和血管内皮生长因子与糖尿病微血管病变的相关性研究[J].福建医药杂志,2024,46(03):9-14.[doi:10.20148/j.fmj.2024.03.003]
　CHEN Duanying,HE Sunben,HUANG Xuri,et al.Correlation between expression of serum MicroRNA-16-5p and vascular endothelial growth factor and diabetic microangiopathy[J].FUJIAN MEDICAL JOURNAL,2024,46(03):9-14.[doi:10.20148/j.fmj.2024.03.003]
点击复制

MicroRNA-16-5p和血管内皮生长因子与糖尿病微血管病变的相关性研究()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年03期
页码:
9-14
栏目:
临床研究
出版日期:
2024-06-15

文章信息/Info

Title:
Correlation between expression of serum MicroRNA-16-5p and vascular endothelial growth factor and diabetic microangiopathy
文章编号:
1002-2600(2024)03-0009-06
作者:
陈端英1; 何孙本1; 黄旭日2; 苏辰夕1; 陈敏2; 宋玲2; 郑建国2
1 福建省福州市第一总医院口腔专科院区检验科,福州 350001; 2 福建省福州市第一总医院口腔专科院区内分泌科,福州 350001
Author(s):
CHEN Duanying1;  HE Sunben1;  HUANG Xuri2;  SU Chenxi1;  CHEN Min2;  SONG Ling2;  ZHENG Jianguo2
1 Clinical Lab of the Dental Specialty Hospital Area of Fuzhou First General Hospital,Fuzhou, Fujian 350001, China; 2 Endocrine Department of the Dental Specialty Hospital Area of Fuzhou First General Hospital, Fuzhou, Fujian 350001, China
关键词:
MicroRNA-16-5p;  血管内皮生长因子;  糖尿病;  糖尿病微血管病变
Keywords:
microRNA-16-5p;  vascular endothelial growth factor;  diabetes;  diabetic microangiopathy
分类号:
R587.1; R587.2
DOI:
10.20148/j.fmj.2024.03.003
文献标志码:
A
摘要:
目的 探讨血清MicroRNA-16-5p(miR-16-5p)和血管内皮生长因子(VEGF)与糖尿病微血管病变(DMVC)的相关性。方法 选取2021年6月至2023年6月收治的2型糖尿病(T2DM)患者作为研究对象,根据是否合并微血管病变分为单纯糖尿病(DM)的DM组(n=20)和发生微血管病变的DMVC组(n=51)。同时选取同期健康体检者作为阴性对照(NC)组(n=20)。统计临床资料,比较各组生化指标,qRT-PCR检测各组血清miR-16-5p的表达以及ELISA试剂盒检测各组血清VEGF的表达。分析糖尿病患者发生微血管病变的危险因素。结果 DM组和DMVC组的DBP、FBG、LDL-C和HbA1c水平高于NC组(P<0.05),DMVC组的BMI、SBP和TG水平高于NC组(P<0.05)。DMVC组血清miR-16-5p水平低于NC和DM组,血清VEGF水平高于NC和DM组,差异有统计学意义(P<0.05)。Pearson相关分析显示血清miR-16-5p表达与VEGF呈负相关(P<0.05)。logistic回归分析显示VEGF和 miR-16-5p表达是糖尿病患者发生微血管病变的影响因素,ROC曲线分析显示血清miR-16-5p、VEGF及两者联合预测糖尿病患者发生微血管病变的曲线下面积(AUC)分别为0.841、0.702和0.837。结论 血清miR-16-5p表达降低与糖尿病的发生发展有关,是发生微血管病变的危险因素,miR-16-5p和VEGF可作为预测糖尿病患者发生微血管病变的潜在生物学标志物。
Abstract:
Objective To investigate the correlation between serum levels of MicroRNA-16-5p(miR-16-5p)and vascular endothelial growth factor(VEGF)and diabetic microangiopathy(DMVC).Methods Type 2 diabetes(T2DM)patients admitted from June 2021 to June 2023 were selected as the study subjects.They were divided into the only diabetes(DM)group(n=20)and the diabetic microangiopathy(DMVC)group(n=51)based on whether they had microvascular complications, and healthy subject in the same period were selected as the negative control(NC)group( n=20).Clinical data of each group were analyzed and compared.The expression of serum miR-16-5p was detected by qRT-PCR and the expression of serum VEGF was detected by ELISA kit.Risk factors for developing microvascular complications in diabetic patients were analyzed.Results The DBP, FBG, LDL-C, and HbA1c levels in the DM and DMVC groups were higher than those in the NC group(P<0.05).The BMI, SBP, and TG levels in the DMVC group were higher than those in the NC group(P<0.05).The serum miR-16-5p level in the DMVC group was lower than that in the NC and DM groups, while the serum VEGF level was higher(P<0.05).Pearson correlation analysis showed thatserum miR-16-5p expression was negatively correlated with VEGF(P<0.05).Logistic regression analysis showed that VEGF and miR-16-5p were influencing factors for the occurrence of microvascular complications in diabetic patients.The ROC curve analysis showed that the area under the curve(AUC)for serum miR-16-5p, VEGF, and their combination in predicting the occurrence of microvascular complications in diabetic patients were 0.841, 0.702, and 0.837, respectively.Conclusion Decreased expression of serum miR-16-5p is associated with the occurrence and development of diabetes and is a risk factor for microvascular complications.miR-16-5p and VEGF can serve as potential biomarkers for predicting the occurrence of microvascular complications in diabetic patients.

参考文献/References:

[1] CROWLEY K, SCANAILL Pó, HERMANIDES J,et al.Current practice in the perioperative management of patients with diabetes mellitus: a narrative review[J].Br J Anaesth, 2023,131(2):242-252.
[2] TU C, WANG L, WEI L.RNA-binding proteins in diabetic microangiopathy[J].J Clin Lab Anal, 2022,36(5): e24407.
[3] LI Y, LIU Y, LIU S,et al.Diabetic vascular diseases: molecular mechanisms and therapeutic strategies[J].Signal Transduct Target Ther, 2023,8(1):152.
[4] DIENER C, KELLER A, MEESE E.Emerging concepts of miRNA therapeutics: from cells to clinic[J].Trends Genet, 2022, 38(6):613-626.
[5] 范泽楠,贺朝晖.糖尿病血管并发症微小RNA研究进展[J].泸州医学院学报, 2019, 42(2):199-204.
[6] CHEN S S, TANG C H, CHIE M J, et al.Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells[J].Cell Death Dis, 2019,10(1):31.
[7] YU T, YOU X, ZHOU H, et al.MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA[J].Aging(Albany NY), 2020,12(10):9500-9514.
[8] CEFALU W T, BUSE J B, TUOMILEHTO J, et al.Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from a diabetes care editors expert forum[J].Diabetes Care, 2016, 39(7):1186-201.
[9] 《中国老年型糖尿病防治临床指南》编写组.中国老年2型糖尿病防治临床指南(2022年版)[J].中国糖尿病杂志, 2022,30(1):2-51.
[10] YANG J, LIU Z.Mechanistic Pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy[J].Front Endocrinol(Lausanne), 2022,13:816400.
[11] SZOSTAK J, GORCY A, DURYS D, et al.The role of MicroRNA in the pathogenesis of diabetic nephropathy[J].Int J Mol Sci, 2023,24(7):6214.
[12] 万淑君,孔祥,吕坤.非编码RNA与糖尿病血管病变的关系[J].上海交通大学学报:医学版, 2021, 41(5):6.
[13] FORRESTER J V, KUFFOVA L, DELIBEGOVIC M.The role of inflammation in diabetic retinopathy[J].Front Immunol, 2020,11:583687.
[14] DING R, ZHU S, ZHAO X,et al.Vascular endothelial growth factor levels in diabetic peripheral neuropathy: a systematic review and meta-analysis[J].Front Endocrinol(Lausanne), 2023, 14: 1238758.
[15] 陈军,周海舟,柏颖,等.葡萄糖-6-磷酸脱氢酶,血管内皮生长因子基因在2型糖尿病患者中的表达及临床价值[J].热带医学杂志, 2020, 20(9):5.
[16] JAIN A, SAXENA S, KHANNA V K, et al.Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus[J].Mol Vis, 2013,19:1760-1768.
[17] GENG T, ZHU K, LU Q,et al.Healthy lifestyle behaviors, mediating biomarkers, and risk of microvascular complications among individuals with type 2 diabetes: A cohort study[J].PLoS Med, 2023, 20(1):e1004135.
[18] PARK S Y, JEONG H J, YANG W M,et al.Implications of microRNAs in the pathogenesis of diabetes[J].Arch Pharm Res, 2013,36(2):154-166.
[19] ZHONG X, CHUNG A C, CHEN H Y, et al.miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes[J].Diabetologia, 2013, 56(3):663-674.
[20] LI E H, HUANG Q Z, LI G C, et al.Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene[J].Biosci Rep, 2017, 37(2):BSR20160572.
[21] 陈云霞,司捷,高倩,等.血浆miR-27在糖尿病视网膜病变患者中的表达及其临床价值[J].国际眼科杂志, 2021, 21(1):5.
[22] RAVECHE E S, SALERNO E, SCAGLIONE B J, et al.Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice[J].Blood,2007, 109(12): 5079-5086.
[23] YANG L, YANG S, REN C, et al.Deciphering the roles of miR-16-5p in malignant solid tumors[J].Biomed Pharmacother, 2022,148:112703.

相似文献/References:

[1]吴火友 向 高 魏金凤 吴祖蛟 穆建成 余桂华.乙酰肝素酶与血管内皮生长因子在结直肠肿瘤组织中的表达及临床意义[J].福建医药杂志,2020,42(06):17.
　WU Huoyou,XIANG Gao,WEI Jinfeng,et al.Expression and significance of HPSE and VEGF in colorectal neoplasms[J].FUJIAN MEDICAL JOURNAL,2020,42(03):17.
[2]梁杰,陈舜喜,卞智淮,等.超声波对兔膝关节骨关节炎关节滑膜和滑液VEGF及MMP-13表达的影响[J].福建医药杂志,2025,47(03):61.[doi:10.20148/j.fmj.2025.03.016]
　LIANG Jie,CHEN Shunxi,BIAN Zhihuai,et al.Influence of ultrasound on expression of VEGF and MMP-13 in joint synovium and synovial fluid of rabbits with knee osteoarthritis[J].FUJIAN MEDICAL JOURNAL,2025,47(03):61.[doi:10.20148/j.fmj.2025.03.016]

备注/Memo

备注/Memo:
基金项目:福州市卫生健康中青年科学研究项目(2021-S-wq34)
更新日期/Last Update: 2024-06-15